← Compound index
COMPOUND RECORD / RETINALAMIN

RetinalaminРетиналамин

A retinal tissue polypeptide extract studied in people with retinal disease, including age-related macular degeneration and pigmentary retinal dystrophy. Studies distinguish injected Retinalamin from oral Normophthal.

Source linked

What the studies found

Randomized study in people · 2026

Retinalamin versus placebo over two years in 21 patients with age-related macular degeneration

Dry AMD mean retinal light sensitivity
+3.27 ± 1.03 dB with Retinalamin−4.14 ± 2.11 dB with placeboDay 720Between-arm difference in change +7.41 dB (p < 0.001)
Wet AMD mean retinal light sensitivity
The within-arm increase with Retinalamin was inconclusive (p = 0.302)−3.57 ± 0.94 dB with placeboDay 720Reported between-arm difference in change +5.57 dB (p < 0.001)
Dry AMD eyes without relative blind spots on testing
27.3% to 100% with Retinalamin (p = 0.002)All placebo eyes had relative blind spots by day 180

At 720 days, mean light sensitivity in dry AMD eyes rose by 3.27 dB with Retinalamin and fell by 4.14 dB with placebo, a reported difference in change of 7.41 dB (p < 0.001). In treated wet AMD eyes, the within-group increase was statistically inconclusive (p = 0.302).

More reported outcomes
Companion electroretinography report
The authors describe differences favoring Retinalamin across most electrical response measures.Exact estimates for individual electrical endpoints require the full tables.
Study notes · methods, sources and limitations

Participants or model 21 people, each with dry AMD in one eye and wet AMD in the other. Retinalamin: 11 people (22 eyes). Placebo: 10 people (20 eyes).

Design Randomized comparison with threshold microperimetry at 76 retinal locations using the Nidek MP-3. Follow-up visits ran from day 90 to day 720. Dry and wet measurements came from fellow eyes in the same participants.

Important limitations

  • The two supplement papers match on sample size, eye diagnoses, intervention and 720-day follow-up, and the microperimetry paper cites the electroretinography paper. They are treated as one cohort. The relationship to the larger RetinGero trial remains unconfirmed. The abstracts leave masking, withdrawals, other eye treatments and adverse-event counts unclear. The study results describe how the retina responded to testing. Effects on visual acuity and disease progression remain unclear.

Russian Ophthalmological Journal. 2026;19(4 Suppl):33–40. · Original journal report

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2024

Retinalamin in diabetic retinopathy: three-month imaging and electrical responses

Ganglion-cell complex (GCL++)
105.45 to 109.14 µm at month 3103.46 to 101.50 µm in controlsp = 0.047 for treated group versus baseline
Full-field ERG magnitude
0.77 to 0.87 µV at month 30.91 to 0.88 µV in controlsp = 0.0489 for treated group versus baseline
Ganglion-cell and inner plexiform layers (GCL+)
63.69 µm at baseline, 61.55 µm at month 1, 65.79 µm at month 365.04, 64.50 and 63.43 µm in controls

At three months, mean ganglion-cell complex thickness went from 105.45 to 109.14 µm with Retinalamin and from 103.46 to 101.50 µm in controls. The paper reports p = 0.047 for change within the treated group.

Study notes · methods, sources and limitations

Participants or model 56 people with type 1 or type 2 diabetes and retinopathy without active macular edema. Retinalamin and comparison arms each included 28 people (56 eyes).

Design Patients received ten daily intramuscular injections or were followed without Retinalamin. The team used optical coherence tomography (OCT) and pattern and full-field electroretinography (ERG) at baseline, month 1 and month 3.

Important limitations

  • The authors explicitly reuse the clinical groups from their earlier functional paper. These are two reports on one 56-person cohort. The groups start with different retinal electrical readings. The reported p values compare treated patients with their own baseline. The paper leaves group assignment, masking and the handling of measurements from both eyes unclear. These measures track retinal structure and electrical function. The data leave vision preservation and long-term disease progression unanswered.

Vestnik Oftalmologii. 2024;140(5):97–104. · Original journal report

Original source or citation ↗

Study results and tables ↗

Observational study · 2015

Retinalamin in retinal dystrophy: a 46-patient long-term comparison

Visual acuity improved after the first course
18/31 (58.1%) with Retinalamin and 4/15 (26.7%) with conventional medications, calculated from the visual acuity categories in Table 1.
Retinal pigmentary degeneration at long-term follow-up
After 23–25 years of Retinalamin, 5/9 had residual vision (0.02–0.04), 1/9 had object vision (0.1 or higher) and 3/9 had complete blindness. All 11 conventional-care patients in this diagnostic subgroup had complete blindness.
Pigmentary degeneration after shorter exposure
Of 15 who received Retinalamin for the first 5–7 years, 5 retained residual vision and 10 had complete blindness at long-term assessment.

Visual acuity improved after the first course in 18/31 Retinalamin recipients and 4/15 comparison patients. After 23–25 years, 6/9 patients with pigmentary retinal dystrophy in the longer-treatment group had residual or object vision versus 0/11 comparison patients.

Study notes · methods, sources and limitations

Participants or model 46 patients (92 eyes): 20 received Retinalamin for 5–7 years, 11 for 23–25 years, and 15 received conventional care.

Design Retinalamin 5 mg by parabulbar injection daily for 10 days (50 mg per course), repeated one to two times per year. The paper compares 20 people with 5–7 years of courses, 11 with 23–25 years of courses and 15 given conventional medications.

Important limitations

  • Treatment groups were defined by access to repeated courses. Selection, baseline differences and retention can influence the long-term comparison. The paper reports patients and eyes separately. The reported outcomes do not establish a separate independent effect for each eye. This study examines pigmentary degeneration and retinal abiotrophy, distinct diagnoses from the early macular degeneration dissertation.
  • The long-term comparison is observational. Duration groups reflect access to repeated courses, with potential differences in baseline severity and retention.

Ophthalmology in Russia. 2015;12(2):43–47. The DOI string carries a different page range. · Original journal report

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Retinalamin

Names in this research collection

Retinal polypeptide complex

Organ-derived peptide research: clinical findings and lineage ↗

Research background

A retinal tissue-derived peptide preparation studied in ophthalmology. It is distinct from the short-peptide catalogue entry Normophthal.

More study findings

Comparison in people · 2016

One versus two Retinalamin courses in dry age-related macular degeneration

Multifocal electroretinography in early or intermediate AMD
Favorable change reported in 80% of casesPeak two months after the first course
Multifocal electroretinography in atrophic AMD
Favorable change in more than 70% of cases after the repeat coursePeak at month 5

In 90 patients, the authors reported improved retinal electrical responses in 80% of early or intermediate cases after treatment. More than 70% of atrophic cases improved after the repeat course.

Study notes · methods, sources and limitations

Participants or model 90 adults aged 47–75 with dry AMD, contributing 180 eyes. One course: 30 people. Repeat course: 60 people.

Design The Helmholtz institute group compared one versus two courses over six months using multifocal electroretinography and other eye assessments.

Important limitations

  • Both groups received active drug. Percentages refer to disease-stage groups described in the paper. Eyes from the same patient are correlated. The retinal electrical response does not establish slower progression or less vision loss.

Russian Ophthalmological Journal. 2016;(1):39–46. · Publication record

Original source or citation ↗

Study results and tables ↗

Trial protocol and enrollment update · 2025

RetinGero dry AMD trial: protocol and preliminary enrollment

RetinGero plans a 240-person placebo-controlled comparison. The protocol article reports 187 enrolled and baseline data for 170 as of January 3, 2025. Comparative efficacy results are pending in the checked publication.

Study notes · methods, sources and limitations

Participants or model Adults aged 60–80 with early or intermediate dry AMD in the study eye and a history of wet AMD in the fellow eye. 240 planned, 120 per group.

Design Multicenter double-blind randomized comparison. The Mandryka military hospital ophthalmology center coordinates the trial with Pirogov University. Assessments include visual acuity, contrast sensitivity, OCT drusen measures and conversion to advanced AMD.

Planned randomization
240 participants, 120 per arm
Documented enrollment and baseline data
187 enrolled. Baseline data available for 170 (84 and 86 by masked group).January 3, 2025
Completed the full cycle
4 participantsSeptember 1, 2025

Important limitations

  • Screening, enrollment, available baseline data and completion represent different denominators. The protocol article gives no between-group efficacy result.
  • The published figures describe recruitment and data availability.

Russian Journal of Clinical Ophthalmology. 2025;25(4):250–256. · Published trial protocol and recruitment update

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2022

Retinalamin schedules and visual-field testing in advanced glaucoma

Retinal photosensitivity
No statistically significant change
Mean deviation across testing programs
−0.36 dB95% CI −4.27 to 3.54

Retinal photosensitivity did not change significantly in this 17-patient schedule comparison. Both groups received Retinalamin.

Study notes · methods, sources and limitations

Participants or model 17 adults with advanced primary open-angle glaucoma, 34 eyes. Nine received courses every three months and eight every six months.

Design Two active schedules compared with automated visual-field testing on different devices and programs.

Important limitations

  • No untreated arm. The 2024 OCT report has the same center, group sizes and schedules. It likely describes the same subgroup.

Russian Open Medical Journal. 2022;11:e0109. · Publication record

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2024

Retinalamin schedules and OCT measurement agreement in advanced glaucoma

Retinal nerve fiber layer thickness agreement
0.69 manual and 0.73 automatic95% CI 0.51–0.81 and 0.57–0.84, respectively
Macular volume agreement
0.21 in both modes

Baseline agreement between OCT devices for retinal nerve fiber layer thickness was 0.69 in manual mode and 0.73 in automatic mode. Agreement for macular volume was 0.21 in both modes.

Study notes · methods, sources and limitations

Participants or model 17 adults, 34 eyes. Nine patients on the three-month schedule and eight on the six-month schedule.

Design Investigators used two OCT systems, tested manual and automated segmentation, and calculated Lin’s concordance correlation coefficients.

Important limitations

  • Both groups received Retinalamin. Device agreement does not establish clinical benefit. The same center and schedules appear in the 2022 visual-field report.

Russian Open Medical Journal. 2024;13:e0307. · Publication record

Original source or citation ↗

Study results and tables ↗

Laboratory analysis · 2017

Measured amino acids in organ peptide preparations

Study of multiple preparations

Retinalamin · measured amino-acid total
563.74 µg/mg lyophilizateTable 2 comparator; taurine 4.1 µg/mg, ornithine not displayed.

This is analytical chemistry, with hydrolysis-released amino acids.

Study notes · methods, sources and limitations

Participants or model Laboratory composition comparison of Cortexin, Cerebrolysin, Retinalamin and Pineamin; three Pineamin manufacturing batches

Design Laboratory composition comparison of Cortexin, Cerebrolysin, Retinalamin and Pineamin; three Pineamin manufacturing batches

Important limitations

  • The comparison does not identify intact peptide sequences or predict effects.
  • Amino-acid totals are not the molecular-mass distribution or an inventory of intact peptides. The mass denominator and formulation excipients matter when comparing liquid and lyophilized organ preparations. Some values in the published table conflict.
  • Chemical characterization helps distinguish the preparations. It cannot establish that amino-acid contents explain stress resistance, and it does not identify which peptides were present.

Bulletin of the Russian Military Medical Academy. 19(1):129–136 · Original journal article

Original source or citation ↗

Study results and tables ↗

Research updates ↗

Compound class
Tissue-derived polypeptide complex
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
St. Petersburg Institute of Bioregulation and Gerontology
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Randomized glaucoma studies and a prospective advanced-glaucoma cohort

Study methods

Clinical findings are mixed; within-group and between-group results are distinguished

Independent replication

Independent replication not established by this collection

Source access

Indexed original abstracts, publisher sources and linked PDFs

Safety evidence

Incomplete assessment; findings do not establish safety for personal use

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The original report and protocol would clarify group sizes, background treatment and translation. Independent replication and equivalence to current products remain uncertain.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗
PEPTIDE RESEARCH / OCT 2026

Related preparations and evidence

Evidence belongs to the preparation actually studied. A tissue extract and a synthetic peptide can belong to the same research tradition without having equivalent effects or safety.

Retina: the molecular link

Retinalamin → Normophthal (adjacent short-peptide program)

Shared tissue theme, not a verified product-to-sequence derivation in this collection.

Clinical evidence and limitations

Randomized glaucoma reports, a 2025 prospective cohort and an active-route comparison are available. Visual acuity and several between-group outcomes were unchanged.

Assess blinding, baseline imbalance, correlated eyes and study overlap. The negative rabbit photochemical-injury experiment is included alongside favorable reports.

Related preparations

Some references concern related extracts, reviews or molecular identification rather than direct studies of this compound.

Explore the full bioregulator collection ↗

View this preparation in the Khavinson evidence map ↗

PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 2 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2009 · RU2373904C1 · Retinalamin plus Cortexin: optic-nerve and retinal methodUse · Corrected visual acuity 0.3 → 0.5; total visual-field expansion reported as 40°

Reported findings

Visual improvement was reported in some eyes, with a persistent non-response in a blind eye.

Glaucoma case: right eye
Corrected visual acuity 0.3 → 0.5; total visual-field expansion reported as 40°After a 10-day courseCombined care in one 76-year-old patient
Glaucoma case: left eye
Visual acuity remained 0After the courseThe eye had longstanding blindness; no recovery was reported
All reported results, comparisons and limitations →

Use. The method combines Retinalamin and Cortexin with physical-treatment procedures for optic-nerve or retinal disease.

Combined treatment and patent case examples do not establish either extract's independent benefit or validate a new administration route.

Publication
RU2373904C1 ↗ · 2009-11-27
Earliest priority / filing
2008-07-08 / 2008-07-08
Original applicant / assignee
Ольга Геннадьевна Гусаревич
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
41476515 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Method of treating diseases of optic nerve and retina

Inventors: Ольга Геннадьевна Гусаревич (RU); Ольга Геннадьевна Гусаревич; Анна Аркадьевна Гусаревич (RU); Анна Аркадьевна Гусаревич; Анжелла Жановна Фурсова (RU); Анжелла Жановна Фурсова.

RU2373904C1

Original patent PDF ↗

Read source review →

2002 · RU2195297C2 · Retinalamin / Cortexin: local ocular delivery methodUse · Acuity increases of 0.01–0.4 and field expansion averaging 10–15° reported

Reported findings

The patent reports visual gains and persistence over follow-up, with two advanced-disease eyes showing no objective benefit.

Visual acuity and fields
Acuity increases of 0.01–0.4 and field expansion averaging 10–15° reported1 weekBefore/after; not an untreated comparison
Additional acuity and field changes
Acuity increased a further 0.05–0.2; fields expanded a further 5–10°1 monthRelative to the preceding examination, as described
All reported results, comparisons and limitations →

Use. The patent describes a surgical delivery method involving retina- or brain-cortex-derived peptide preparations; the description identifies Retinalamin and Cortexin.

This is a delivery-method disclosure, not proof of safety or superiority of an invasive route. It must not be counted as independent clinical replication without checking related reports.

Publication
RU2195297C2 ↗ · 2002-12-27
Earliest priority / filing
2000-01-20 / 2000-01-20
Original applicant / assignee
Общество с ограниченной ответственностью "Клиника Института биорегуляции и геронтологии"
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
20229433 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Method for treating dystrophic diseases of eyes

Inventors: И.Б. Максимов; В.Х. Хавинсон; Л.К. Мошетова; Г.В. Анисимова.

RU2195297C2

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Comparison in people · 2024

Retinalamin in diabetic retinopathy: three-month imaging and electrical responses

At three months, mean ganglion-cell complex thickness went from 105.45 to 109.14 µm with Retinalamin and from 103.46 to 101.50 µm in controls. The paper reports p = 0.047 for change within the treated group.

Ganglion-cell complex (GCL++) · 105.45 to 109.14 µm at month 3 · 103.46 to 101.50 µm in controls · p = 0.047 for treated group versus baseline

Study notes and original source
2024Human comparative studyFull text available

Retinalamin in diabetic retinopathy: three-month imaging and electrical responses

Intramuscular Retinalamin (Geropharm) · Original journal report

A. I. Malakhova, V. V. Strakhov, Y. A. Malakhova · Vestnik Oftalmologii. 2024;140(5):97–104.

At three months, mean ganglion-cell complex thickness went from 105.45 to 109.14 µm with Retinalamin and from 103.46 to 101.50 µm in controls. The paper reports p = 0.047 for change within the treated group.

Results and tables

Reported findings and study design

Patients received ten daily intramuscular injections or were followed without Retinalamin. The team used optical coherence tomography (OCT) and pattern and full-field electroretinography (ERG) at baseline, month 1 and month 3.

Population or model 56 people with type 1 or type 2 diabetes and retinopathy without active macular edema. Retinalamin and comparison arms each included 28 people (56 eyes).

Dose, route and schedule

Ten daily intramuscular injections, with assessments at baseline and months 1 and 3. The papers leave the mass per injection unspecified. The earlier paper describes the Diopsys functional assessment in the same clinical groups.

Protocol source ↗ · Companion functional paper, confirmed cohort reuse in the later article

Results · Original article, methods and Tables 1–2
MeasureResultComparison, timing and statistics
Ganglion-cell complex (GCL++)105.45 to 109.14 µm at month 3103.46 to 101.50 µm in controls · p = 0.047 for treated group versus baseline
Full-field ERG magnitude0.77 to 0.87 µV at month 30.91 to 0.88 µV in controls · p = 0.0489 for treated group versus baseline
Ganglion-cell and inner plexiform layers (GCL+)63.69 µm at baseline, 61.55 µm at month 1, 65.79 µm at month 365.04, 64.50 and 63.43 µm in controls
Selected OCT and ERG means by visit
Selected OCT and ERG means by visit
Measure and groupBaselineMonth 1Month 3Month 3 vs baseline
GCL++ (µm), Retinalamin105.45106.76109.14p = 0.047
GCL++ (µm), comparison103.46102.81101.50p unspecified
Nerve fiber layer (µm), Retinalamin41.6643.1043.41p = 0.048
Nerve fiber layer (µm), comparison38.4338.3138.07p unspecified
Pattern ERG magnitude at 100% (µV), Retinalamin0.981.201.18p = 0.028
Pattern ERG magnitude at 100% (µV), comparison1.271.261.26p unspecified
Full-field ERG magnitude (µV), Retinalamin0.770.850.87p = 0.0489
Full-field ERG magnitude (µV), comparison0.910.920.88p unspecified

The publication provides confidence intervals for arm means. The p values shown test change within the Retinalamin arm.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
56 people with type 1 or type 2 diabetes and retinopathy without active macular edema. Retinalamin and comparison arms each included 28 people (56 eyes).
Source reviewed
Original Russian full article, Tables 1–2 and companion functional report.
Study limitations
  • The authors explicitly reuse the clinical groups from their earlier functional paper. These are two reports on one 56-person cohort.
  • The groups start with different retinal electrical readings. The reported p values compare treated patients with their own baseline. The paper leaves group assignment, masking and the handling of measurements from both eyes unclear.
  • These measures track retinal structure and electrical function. The data leave vision preservation and long-term disease progression unanswered.

Reviewed 2026-11-16.

Read the source ↗

Randomized study in people · 2026

Retinalamin versus placebo over two years in 21 patients with age-related macular degeneration

At 720 days, mean light sensitivity in dry AMD eyes rose by 3.27 dB with Retinalamin and fell by 4.14 dB with placebo, a reported difference in change of 7.41 dB (p < 0.001). In treated wet AMD eyes, the within-group increase was statistically inconclusive (p = 0.302).

Dry AMD mean retinal light sensitivity · +3.27 ± 1.03 dB with Retinalamin · −4.14 ± 2.11 dB with placebo · Day 720 · Between-arm difference in change +7.41 dB (p < 0.001)

Study notes and original source
2026Randomized trialRussian-language source

Retinalamin versus placebo over two years in 21 patients with age-related macular degeneration

Repeated intramuscular Retinalamin versus placebo · Original journal report

V. V. Neroev, S. V. Milash · Russian Ophthalmological Journal. 2026;19(4 Suppl):33–40.

At 720 days, mean light sensitivity in dry AMD eyes rose by 3.27 dB with Retinalamin and fell by 4.14 dB with placebo, a reported difference in change of 7.41 dB (p < 0.001). In treated wet AMD eyes, the within-group increase was statistically inconclusive (p = 0.302).

Results and tables

Reported findings and study design

Randomized comparison with threshold microperimetry at 76 retinal locations using the Nidek MP-3. Follow-up visits ran from day 90 to day 720. Dry and wet measurements came from fellow eyes in the same participants.

Population or model 21 people, each with dry AMD in one eye and wet AMD in the other. Retinalamin: 11 people (22 eyes). Placebo: 10 people (20 eyes).

Dose, route and schedule

The companion electroretinography paper describes eight 10-day intramuscular courses at 90-day intervals. The accessible abstracts leave the mass per dose unspecified.

Protocol source ↗ · Companion paper from the same journal supplement

Results · Original microperimetry abstract and companion electroretinography abstract
MeasureResultComparison, timing and statistics
Dry AMD mean retinal light sensitivity+3.27 ± 1.03 dB with Retinalamin−4.14 ± 2.11 dB with placebo · Day 720 · Between-arm difference in change +7.41 dB (p < 0.001)
Wet AMD mean retinal light sensitivityThe within-arm increase with Retinalamin was inconclusive (p = 0.302)−3.57 ± 0.94 dB with placebo · Day 720 · Reported between-arm difference in change +5.57 dB (p < 0.001)
Dry AMD eyes without relative blind spots on testing27.3% to 100% with Retinalamin (p = 0.002)All placebo eyes had relative blind spots by day 180
Companion electroretinography reportThe authors describe differences favoring Retinalamin across most electrical response measures.Exact estimates for individual electrical endpoints require the full tables.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
21 people, each with dry AMD in one eye and wet AMD in the other. Retinalamin: 11 people (22 eyes). Placebo: 10 people (20 eyes).
Source reviewed
Original Russian abstracts for the microperimetry and companion electroretinography reports.
Study limitations
  • The two supplement papers match on sample size, eye diagnoses, intervention and 720-day follow-up, and the microperimetry paper cites the electroretinography paper. They are treated as one cohort. The relationship to the larger RetinGero trial remains unconfirmed.
  • The abstracts leave masking, withdrawals, other eye treatments and adverse-event counts unclear. The study results describe how the retina responded to testing. Effects on visual acuity and disease progression remain unclear.

Reviewed 2026-11-16.

Read the source ↗

Observational study · 2015

Retinalamin in retinal dystrophy: a 46-patient long-term comparison

Visual acuity improved after the first course in 18/31 Retinalamin recipients and 4/15 comparison patients. After 23–25 years, 6/9 patients with pigmentary retinal dystrophy in the longer-treatment group had residual or object vision versus 0/11 comparison patients.

Visual acuity improved after the first course · 18/31 (58.1%) with Retinalamin and 4/15 (26.7%) with conventional medications, calculated from the visual acuity categories in Table 1.

Study notes and original source
2015Uncontrolled human reportFull text available

Retinalamin in retinal dystrophy: a 46-patient long-term comparison

Parabulbar Retinalamin, repeated courses · Original journal report

M. I. Razumovskiy, K. M. Pavlyuchenko, A. M. Razumovskaya · Ophthalmology in Russia. 2015;12(2):43–47. The DOI string carries a different page range.

Visual acuity improved after the first course in 18/31 Retinalamin recipients and 4/15 comparison patients. After 23–25 years, 6/9 patients with pigmentary retinal dystrophy in the longer-treatment group had residual or object vision versus 0/11 comparison patients.

Results and tables

Reported findings and study design

Retinalamin 5 mg by parabulbar injection daily for 10 days (50 mg per course), repeated one to two times per year. The paper compares 20 people with 5–7 years of courses, 11 with 23–25 years of courses and 15 given conventional medications.

Population or model 46 patients (92 eyes): 20 received Retinalamin for 5–7 years, 11 for 23–25 years, and 15 received conventional care.

Results · Original journal PDF, methods and Tables 1 and 4
MeasureResultComparison, timing and statistics
Visual acuity improved after the first course18/31 (58.1%) with Retinalamin and 4/15 (26.7%) with conventional medications, calculated from the visual acuity categories in Table 1.
Retinal pigmentary degeneration at long-term follow-upAfter 23–25 years of Retinalamin, 5/9 had residual vision (0.02–0.04), 1/9 had object vision (0.1 or higher) and 3/9 had complete blindness. All 11 conventional-care patients in this diagnostic subgroup had complete blindness.
Pigmentary degeneration after shorter exposureOf 15 who received Retinalamin for the first 5–7 years, 5 retained residual vision and 10 had complete blindness at long-term assessment.

The long-term comparison is observational. Duration groups reflect access to repeated courses, with potential differences in baseline severity and retention.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
46 patients (92 eyes): 20 received Retinalamin for 5–7 years, 11 for 23–25 years, and 15 received conventional care.
Source reviewed
Original bilingual full article, methods and Tables 1 and 4.
Study limitations
  • Treatment groups were defined by access to repeated courses. Selection, baseline differences and retention can influence the long-term comparison.
  • The paper reports patients and eyes separately. The reported outcomes do not establish a separate independent effect for each eye.
  • This study examines pigmentary degeneration and retinal abiotrophy, distinct diagnoses from the early macular degeneration dissertation.

Reviewed 2026-11-16.

Read the source ↗

Comparison in people · 2021

Retinalamin with Cortexin and Ventfort Lingval in dry age-related macular degeneration

Visual acuity went from 0.71 to 0.76 with Retinalamin alone and from 0.76 to 0.88 with the combination. This comparison used electrophoresis for the two added preparations.

Study notes and original source
2021Human comparative studyFull text available

Retinalamin with Cortexin and Ventfort Lingval in dry age-related macular degeneration

Temporal paravascular Retinalamin injections with or without Cortexin and Ventfort Lingval by electrophoresis · Original journal report

A. V. Derkach, S. V. Trofimova · Vrach. 2021;32(5):85–87.

Visual acuity went from 0.71 to 0.76 with Retinalamin alone and from 0.76 to 0.88 with the combination. This comparison used electrophoresis for the two added preparations.

Results and tables

Reported findings and study design

Five courses, repeated one to two times per year. The methods list temporal paravascular Retinalamin 5 mg daily for 10 days in both groups. In the combination group, Cortexin and Ventfort Lingval were given by cathodal drug electrophoresis daily for five days, 20 minutes per session at up to 0.1 mA/cm². Active mass for the two electrophoresis preparations was unspecified.

Population or model 38 patients (76 eyes) with nonexudative macular degeneration: 20 Retinalamin alone, 18 the combination.

Results · Original publisher PDF, methods and Tables 1–2
MeasureResultComparison, timing and statistics
Visual acuityRetinalamin alone 0.71 ± 0.05 to 0.76 ± 0.04. Combination 0.76 ± 0.05 to 0.88 ± 0.04.
Electroretinogram a-wave amplitudeRetinalamin alone 21.2 ± 1.5 to 28.1 ± 1.7 µV. Combination 21.4 ± 1.5 to 33.9 ± 1.5 µV.
Electroretinogram b-wave amplitudeRetinalamin alone 173.7 ± 8.1 to 222.7 ± 6.6 µV. Combination 172.8 ± 8.6 to 250.0 ± 7.3 µV.

The combination adds two preparations and a different procedure. The report supplies no treatment-specific estimate for Cortexin or Ventfort Lingval and no between-group confidence intervals.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
38 patients (76 eyes) with nonexudative macular degeneration: 20 Retinalamin alone, 18 the combination.
Source reviewed
Original Russian article, treatment methods and Tables 1 and 2.
Study limitations
  • The report gives no randomization or masking method and the groups start with different acuity values. The contribution of each added preparation and electrophoresis cannot be isolated.
  • The methods name Retinalamin but also describe Retilin in the adjacent text. The authors leave the mass applied by electrophoresis unspecified.
  • The narrative percentages lack clear denominators. The tables contain no between-group p values or confidence intervals. Independent overlap with other retina cohorts is unspecified.

Reviewed 2026-11-16.

Read the source ↗

Randomized study in people · 2013

Normophthal added to Retinalamin for early age-related macular degeneration

After 40 days, uncorrected visual acuity in the 45–59-year subgroup was 0.62 with adjunctive Normophthal and 0.60 with Retinalamin alone. The author reports no significant additional clinical effect in the oldest subgroup.

Study notes and original source
2013Randomized trialRussian-language source

Normophthal added to Retinalamin for early age-related macular degeneration

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology

Oral Normophthal after injected Retinalamin versus injected Retinalamin alone · Dissertation author abstract

Format: Reproduction of Russian author abstract · Reviewed: See scope

A. V. Gorbunov · Candidate of Medical Sciences dissertation author abstract. St. Petersburg, 2013. Catalogue identifier 005531262.

After 40 days, uncorrected visual acuity in the 45–59-year subgroup was 0.62 with adjunctive Normophthal and 0.60 with Retinalamin alone. The author reports no significant additional clinical effect in the oldest subgroup.

Results and tables

Reported findings and study design

67 patients received combination treatment and 53 received Retinalamin only. The author describes stratified randomization. Visual testing occurred at baseline, day 40 and three months after treatment.

Population or model 120 patients with early age-related macular degeneration, 213 eyes: 67 in the combination group and 53 in the Retinalamin group.

Results · 2013 dissertation author abstract, study design and visual outcomes
MeasureResultComparison, timing and statistics
Study regimenBoth groups received 5 mg Retinalamin by parabulbar injection each day for 10 days. The combination group then received 100 µg Normophthal orally twice daily for 30 days.
Uncorrected visual acuity at day 40, ages 45–590.62 ± 0.04 with the combination and 0.60 ± 0.04 with Retinalamin alone. The reported pretreatment value was 0.47 ± 0.04.
Oldest subgroup, ages 75–89The author reports no significant additional clinical effect with Normophthal in this subgroup.

The author abstract identifies the Ophthalmology Laboratory of the St. Petersburg Institute of Bioregulation and Gerontology as the research institution. Both groups received Retinalamin.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
120 patients with early age-related macular degeneration, 213 eyes: 67 in the combination group and 53 in the Retinalamin group.
Source reviewed
Russian author abstract, methods and results on pages 10–21. The full dissertation was unavailable.
Study limitations
  • The author reports stratified randomization. Details of concealment and masking are unavailable.
  • The 45–59-year result is one age subgroup. The cited values alone do not establish a statistically significant difference between arms.
  • The 45-patient 2013 Kazakhstan paper is a separate publication with different authors and group sizes. The available records do not establish cohort overlap.

Reviewed 2026-11-16.

Read the source ↗

Comparison in people · 2016

One versus two Retinalamin courses in dry age-related macular degeneration

In 90 patients, the authors reported improved retinal electrical responses in 80% of early or intermediate cases after treatment. More than 70% of atrophic cases improved after the repeat course.

Study notes and original source
2016Human comparative studyFull text available

One versus two Retinalamin courses in dry age-related macular degeneration

V. V. Neroev, O. V. Zaitseva, T. D. Okhotsimskaya, I. V. Tsapenko, E. P. Lantukh · Russian Ophthalmological Journal. 2016;(1):39–46.

In 90 patients, the authors reported improved retinal electrical responses in 80% of early or intermediate cases after treatment. More than 70% of atrophic cases improved after the repeat course.

Results and tables

Reported findings and study design

The Helmholtz institute group compared one versus two courses over six months using multifocal electroretinography and other eye assessments.

Population or model 90 adults aged 47–75 with dry AMD, contributing 180 eyes. One course: 30 people. Repeat course: 60 people.

Dose, route and schedule

Retinalamin 5 mg intramuscularly daily for 10 days. Sixty participants repeated the same course after three months. Thirty received one course.

Protocol source ↗ · Original Russian journal PDF, abstract, methods and longitudinal results.

Results · Original Russian journal PDF, abstract, methods and longitudinal results.
MeasureResultComparison, timing and statistics
Multifocal electroretinography in early or intermediate AMDFavorable change reported in 80% of casesPeak two months after the first course
Multifocal electroretinography in atrophic AMDFavorable change in more than 70% of cases after the repeat coursePeak at month 5

Source for these results ↗ · Reviewed 2026-11-15

Population / setting
90 adults aged 47–75 with dry AMD, contributing 180 eyes. One course: 30 people. Repeat course: 60 people.
Source reviewed
Original Russian journal PDF, abstract, methods and longitudinal results.
Study limitations
  • Both groups received active drug. Percentages refer to disease-stage groups described in the paper. Eyes from the same patient are correlated. The retinal electrical response does not establish slower progression or less vision loss.

Reviewed 2026-11-15.

Read the source ↗

Trial protocol and enrollment update · 2025

RetinGero dry AMD trial: protocol and preliminary enrollment

RetinGero plans a 240-person placebo-controlled comparison. The protocol article reports 187 enrolled and baseline data for 170 as of January 3, 2025. Comparative efficacy results are pending in the checked publication.

Study notes and original source
2025Trial protocol / registrationFull text available

RetinGero dry AMD trial: protocol and preliminary enrollment

· Published trial protocol and recruitment update

A. V. Kuroyedov, E. V. Balandina, O. V. Gaponko, and colleagues · Russian Journal of Clinical Ophthalmology. 2025;25(4):250–256.

RetinGero plans a 240-person placebo-controlled comparison. The protocol article reports 187 enrolled and baseline data for 170 as of January 3, 2025. Comparative efficacy results are pending in the checked publication.

Results and tables

Reported findings and study design

The patent gives no measured outcomes

Multicenter double-blind randomized comparison. The Mandryka military hospital ophthalmology center coordinates the trial with Pirogov University. Assessments include visual acuity, contrast sensitivity, OCT drusen measures and conversion to advanced AMD.

Dose, route and schedule

The protocol lists a 5 mg Retinalamin vial. It specifies one intramuscular injection per day for 10 days, repeated for eight courses spaced three months apart. The comparator is a matching schedule of placebo injections.

Protocol source ↗ · Original protocol, planned assessments and dated enrollment data.

Results · Original protocol, planned assessments and dated enrollment data.
MeasureResultComparison, timing and statistics
Planned randomization240 participants, 120 per arm
Documented enrollment and baseline data187 enrolled. Baseline data available for 170 (84 and 86 by masked group).January 3, 2025
Completed the full cycle4 participantsSeptember 1, 2025

The published figures describe recruitment and data availability.

Source for these results ↗ · Reviewed 2026-11-15

Population / setting
Adults aged 60–80 with early or intermediate dry AMD in the study eye and a history of wet AMD in the fellow eye. 240 planned, 120 per group.
Source reviewed
Original protocol, planned assessments and dated enrollment data.
Study limitations
  • Screening, enrollment, available baseline data and completion represent different denominators. The protocol article gives no between-group efficacy result.

Reviewed 2026-11-15.

Read the source ↗

Comparison in people · 2022

Retinalamin schedules and visual-field testing in advanced glaucoma

Retinal photosensitivity did not change significantly in this 17-patient schedule comparison. Both groups received Retinalamin.

Study notes and original source
2022Human comparative studyFull text available

Retinalamin schedules and visual-field testing in advanced glaucoma

D. A. Dorofeev and colleagues · Russian Open Medical Journal. 2022;11:e0109.

Retinal photosensitivity did not change significantly in this 17-patient schedule comparison. Both groups received Retinalamin.

Results and tables

Reported findings and study design

Two active schedules compared with automated visual-field testing on different devices and programs.

Population or model 17 adults with advanced primary open-angle glaucoma, 34 eyes. Nine received courses every three months and eight every six months.

Dose, route and schedule

Repeat courses every three or six months. The paper describes intramuscular delivery. The administered mass was not verified from this report.

Protocol source ↗ · Original journal full text, methods and Tables 1–3.

Results · Original journal full text, methods and Tables 1–3.
MeasureResultComparison, timing and statistics
Retinal photosensitivityNo statistically significant change
Mean deviation across testing programs−0.36 dB95% CI −4.27 to 3.54

Source for these results ↗ · Reviewed 2026-11-14

Population / setting
17 adults with advanced primary open-angle glaucoma, 34 eyes. Nine received courses every three months and eight every six months.
Source reviewed
Original journal full text, methods and Tables 1–3.
Study limitations
  • No untreated arm. The 2024 OCT report has the same center, group sizes and schedules. It likely describes the same subgroup.

Reviewed 2026-11-14.

Read the source ↗

Comparison in people · 2024

Retinalamin schedules and OCT measurement agreement in advanced glaucoma

Baseline agreement between OCT devices for retinal nerve fiber layer thickness was 0.69 in manual mode and 0.73 in automatic mode. Agreement for macular volume was 0.21 in both modes.

Study notes and original source
2024Human comparative studyFull text available

Retinalamin schedules and OCT measurement agreement in advanced glaucoma

D. A. Dorofeev, A. A. Antonov, I. V. Kozlova, and colleagues · Russian Open Medical Journal. 2024;13:e0307.

Baseline agreement between OCT devices for retinal nerve fiber layer thickness was 0.69 in manual mode and 0.73 in automatic mode. Agreement for macular volume was 0.21 in both modes.

Results and tables

Reported findings and study design

Investigators used two OCT systems, tested manual and automated segmentation, and calculated Lin’s concordance correlation coefficients.

Population or model 17 adults, 34 eyes. Nine patients on the three-month schedule and eight on the six-month schedule.

Dose, route and schedule

Intramuscular Retinalamin courses at three- or six-month intervals. Structural OCT was performed at baseline and after three and six months. Drug mass was not verified from the report.

Protocol source ↗ · Original PDF, methods and optical coherence tomography agreement results.

Results · Original PDF, methods and optical coherence tomography agreement results.
MeasureResultComparison, timing and statistics
Retinal nerve fiber layer thickness agreement0.69 manual and 0.73 automatic95% CI 0.51–0.81 and 0.57–0.84, respectively
Macular volume agreement0.21 in both modes

Source for these results ↗ · Reviewed 2026-11-14

Population / setting
17 adults, 34 eyes. Nine patients on the three-month schedule and eight on the six-month schedule.
Source reviewed
Original PDF, methods and optical coherence tomography agreement results.
Study limitations
  • Both groups received Retinalamin. Device agreement does not establish clinical benefit. The same center and schedules appear in the 2022 visual-field report.

Reviewed 2026-11-14.

Read the source ↗

Laboratory analysis · 2017

Amino-acid analysis of Pineamin and three organ peptide preparations

This is analytical chemistry, with hydrolysis-released amino acids.

Study notes and original source
2017Analytical / composition studyFull text available

Amino-acid analysis of Pineamin and three organ peptide preparations

Free and hydrolysis-released amino acids; the measurements do not identify intact peptide sequences. · Original journal article

Format: Original publisher text and Table 2 checked; selected three-batch arithmetic audited, original PDF not recovered · Reviewed: Reported methods, results and evidence limitations

A. O. Rudenko, T. E. Eltysheva, M. M. Dyakonov · Bulletin of the Russian Military Medical Academy. 19(1):129–136

Pineamin’s reported measured amino-acid total was 731.23 µg/mg of lyophilizate. Taurine and ornithine were detected, and three reported batch averages do not match the displayed batch values.

Results and tables

Reported findings and study design

Pineamin’s reported measured amino-acid total was 731.23 µg/mg of lyophilizate. Taurine and ornithine were detected, and three reported batch averages do not match the displayed batch values.

Laboratory composition comparison of Cortexin, Cerebrolysin, Retinalamin and Pineamin; three Pineamin manufacturing batches

Population or model Laboratory composition comparison of Cortexin, Cerebrolysin, Retinalamin and Pineamin; three Pineamin manufacturing batches

Results · Original publisher text and Table 2 checked; selected three-batch arithmetic audited, original PDF not recovered
MeasureResultComparison, timing and statistics
Pineamin · reported amino-acid total731.23 µg/mg lyophilizateBatch totals 736.5, 713.7 and 743.5 µg/mg; Table 2.
Pineamin · selected amino acidsGlu 168.23; Asp 82.70; Lys 67.80; taurine 7.93; ornithine 18.47 µg/mgReported Table 2 averages; these do not identify intact peptides.
Retinalamin · measured amino-acid total563.74 µg/mg lyophilizateTable 2 comparator; taurine 4.1 µg/mg, ornithine not displayed.
Cortexin versus Cerebrolysin · compositionHigher Cortexin amounts of several amino acids per mg of preparationThe authors report roughly 6.5–7-fold for Asp, Glu and Tyr, ninefold for serine and twelvefold for arginine. This is a chemical comparison.
Batch-average discrepanciesMet 8.55 reported vs 7.50 recalculated; Ile 22.35 vs 27.73; Leu 39.50 vs 33.53 µg/mgArithmetic means calculated from the three displayed values. The cause of the disagreement is unresolved.
Table 2 · selected Pineamin batch values (µg/mg)
Table 2 · selected Pineamin batch values (µg/mg)
AnalyteBatch 1Batch 2Batch 3Printed meanRecalculated mean if discrepant
Asp8678.383.882.70—
Glu171.1161.6172168.23—
Lys67.565.870.167.80—
Taurine9.157.277.377.93—
Ornithine18.720.616.118.47—
Met8.298.815.418.557.50
Ile21.938.522.822.3527.73
Leu38.621.640.439.5033.53
Total736.5713.7743.5731.23—

Selected published rows. Recalculated values identify reporting inconsistencies; the printed averages are preserved. These are amino acids measured in the preparation, not individual peptide sequences.

Chemical characterization helps distinguish the preparations. It cannot establish that amino-acid contents explain stress resistance, and it does not identify which peptides were present.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
Laboratory composition comparison of Cortexin, Cerebrolysin, Retinalamin and Pineamin; three Pineamin manufacturing batches
Source reviewed
Original publisher text and Table 2 checked; selected three-batch arithmetic audited, original PDF not recovered
Study limitations
  • Amino-acid totals are not the molecular-mass distribution or an inventory of intact peptides.
  • The mass denominator and formulation excipients matter when comparing liquid and lyophilized organ preparations.
  • Some values in the published table conflict.

Reviewed 2026-11-08.

Read the source ↗

Experiment described in a patent · 2009

Retinalamin plus Cortexin: optic-nerve and retinal method — RU2373904C1

Visual improvement was reported in some eyes, with a persistent non-response in a blind eye.

Study notes and original source
2009Patent / reported experimentsFull text available

Retinalamin plus Cortexin: optic-nerve and retinal method — RU2373904C1

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Ольга Геннадьевна Гусаревич (RU), Ольга Геннадьевна Гусаревич, Анна Аркадьевна Гусаревич (RU), Анна Аркадьевна Гусаревич, Анжелла Жановна Фурсова (RU), Анжелла Жановна Фурсова · RU2373904C1 · patent family 41476515

Visual improvement was reported in some eyes, with a persistent non-response in a blind eye.

Results and tables

Reported patent results

Reported findings

Visual improvement was reported in some eyes, with a persistent non-response in a blind eye.

Two illustrative eye-disease cases receiving Retinalamin, Cortexin and physical-treatment procedures.

Population or model Two illustrative eye-disease cases receiving Retinalamin, Cortexin and physical-treatment procedures.

Results · Description: clinical Examples 1 and 2, including unchanged left-eye measurements.
MeasureResultComparison, timing and statistics
Glaucoma case: right eyeCorrected visual acuity 0.3 → 0.5; total visual-field expansion reported as 40°Combined care in one 76-year-old patient · After a 10-day course
Glaucoma case: left eyeVisual acuity remained 0The eye had longstanding blindness; no recovery was reported · After the course
Other case: left eye at dischargeVisual acuity reported as 0.2, without correctionAn individual post-treatment value, not a group mean

Two selected cases and multiple procedures cannot establish either peptide preparation’s independent effect, safety of the route, or a reliable comparative benefit.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Two illustrative eye-disease cases receiving Retinalamin, Cortexin and physical-treatment procedures.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • Combined treatment and patent case examples do not establish either extract's independent benefit or validate a new administration route.
  • Two selected cases and multiple procedures cannot establish either peptide preparation’s independent effect, safety of the route, or a reliable comparative benefit.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Experiment described in a patent · 2002

Retinalamin / Cortexin: local ocular delivery method — RU2195297C2

The patent reports visual gains and persistence over follow-up, with two advanced-disease eyes showing no objective benefit.

Study notes and original source
2002Patent / reported experimentsFull text available

Retinalamin / Cortexin: local ocular delivery method — RU2195297C2

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

И.Б. Максимов, В.Х. Хавинсон, Л.К. Мошетова, Г.В. Анисимова · RU2195297C2 · patent family 20229433

The patent reports visual gains and persistence over follow-up, with two advanced-disease eyes showing no objective benefit.

Results and tables

Reported patent results

Reported findings

The patent reports visual gains and persistence over follow-up, with two advanced-disease eyes showing no objective benefit.

Uncontrolled patent report of 65 patients (80 eyes), aged 18–80, receiving local delivery of retina- or cortex-derived preparations.

Population or model Uncontrolled patent report of 65 patients (80 eyes), aged 18–80, receiving local delivery of retina- or cortex-derived preparations.

Results · Description: 65-patient clinical observations and follow-up summary.
MeasureResultComparison, timing and statistics
Visual acuity and fieldsAcuity increases of 0.01–0.4 and field expansion averaging 10–15° reportedBefore/after; not an untreated comparison · 1 week
Additional acuity and field changesAcuity increased a further 0.05–0.2; fields expanded a further 5–10°Relative to the preceding examination, as described · 1 month
Persistence and non-responseResults described as stable at 3 and 6 months; no objective positive effect in two advanced-disease eyesFollow-up duration varied from 1 to 6 months
Reported tolerabilityNo allergic or adverse effects reportedUncontrolled reporting does not establish safety of invasive delivery

Heterogeneous diagnoses, non-independent eyes and absence of a concurrent control prevent causal inference. Results cannot be assigned to both extracts as if each had been independently tested.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Uncontrolled patent report of 65 patients (80 eyes), aged 18–80, receiving local delivery of retina- or cortex-derived preparations.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • This is a delivery-method disclosure, not proof of safety or superiority of an invasive route. It must not be counted as independent clinical replication without checking related reports.
  • Heterogeneous diagnoses, non-independent eyes and absence of a concurrent control prevent causal inference. Results cannot be assigned to both extracts as if each had been independently tested.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Randomized study in people · 2020

The influence of long-term retinal protective therapy on glaucoma progression according to structural and functional tests

Retinal nerve-fiber thickness remained stable within the treated group and declined within controls, but endpoint differences between groups were not significant. Visual acuity and mean deviation did not significantly change; pattern standard deviation worsened in both groups.

Study notes and original source
2020Randomized trialEnglish abstract

The influence of long-term retinal protective therapy on glaucoma progression according to structural and functional tests

Retinalamin tissue-derived preparation

Strakhov VV, Egorov EA, Erichev VP, Yartsev AV, Petrov SY, Dorofeev DA · Vestnik oftalmologii. 2020;136:58-66.

Retinal nerve-fiber thickness remained stable within the treated group and declined within controls, but endpoint differences between groups were not significant. Visual acuity and mean deviation did not significantly change; pattern standard deviation worsened in both groups.

Results and tables

Reported findings and study design

147 glaucoma patients, 249 eyes: Retinalamin 69 patients/119 eyes versus control 78/130. Repeat courses every six months; assessments every three months for 24 months.

Population or model 147 patients (249 eyes), randomized; 24 months

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Visual acuity/refractionNo change in either groupp>0.05
IOPIncreased in controls (p=0.033); end-of-study groups not differentbetween-group p=0.87
Mean deviation changeNot significant in either groupp=0.45 treated; p=0.27 control
PSD, treated4.84 ± 3.21 → 6.01 ± 2.584 dBp=0.0004
PSD, control3.46 ± 2.23 → 5.86 ± 2.26 dBp<0.0001
PSD between groupsBaseline p=0.02; end p=0.53
MD between groupsBaseline p=0.15; end p=0.59
RNFLTreated change p=0.078; control 83.5 ± 22.47 → 76.7 ± 20.7 μm (p=0.001)Between groups: baseline p=0.276; end p=0.524
Neuroretinal rimTreated 222 ± 88.94 → 231 ± 99.3 (p=0.012); control 248 ± 87.09 → 234 ± 96.2 (p=0.0006)Between groups p=0.109 baseline; p=0.909 end; units not given
Ganglion-cell-layer thicknessNo significant changesWithin groups p=0.211/0.16; between groups p=0.44/0.51

Within-group significance is not evidence of a significant treatment-versus-control difference. Patient and eye counts are kept distinct.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting
147 patients (249 eyes), randomized; 24 months
Source reviewed
PubMed-indexed abstract and bibliographic metadata checked via Europe PMC; full methods not appraised.
Study limitations
  • Within-group significance is not evidence of a between-group treatment effect.
  • Blinding and adjustment for two eyes per participant require full-methods review.

Reviewed 2026-10-07.

Read the source ↗

Animal research · 2021

Retinoprotective effects of Retinalamin studied in an experimental model of photochemical damage to rabbit retinas

Retinalamin did not significantly improve electroretinography, retinal morphology or apoptosis measures versus saline in this photochemical retinal-injury model.

Retinal functional changes after injury · Declines on days 10/20 · p<0.001 versus baseline

Study notes and original source
2021Animal / experimentalEnglish abstract

Retinoprotective effects of Retinalamin studied in an experimental model of photochemical damage to rabbit retinas

Retinalamin tissue-derived preparation

Suetov AA, Alekperov SI, Odinokaya MA, Kostina AA · Vestnik oftalmologii. 2021;137:57-67.

Retinalamin did not significantly improve electroretinography, retinal morphology or apoptosis measures versus saline in this photochemical retinal-injury model.

Results and tables

Reported findings and study design

36 rabbits, 72 eyes, randomized into four equal groups. Retinalamin 0.25 mg/kg parabulbar for ten days, starting day 1 or 10; matching saline groups. Injury: 405 nm light, 5 mW/cm², four hours/day for 20 days.

Population or model 36 rabbits (72 eyes), four randomized groups

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Retinal functional changes after injuryDeclines on days 10/20p<0.001 versus baseline
Retinalamin versus salineNo significant difference on any measured endpointp>0.05
Assessment timesBaseline and days 10, 20 and 30

Rabbit photochemical-injury model; the negative drug comparison is preserved.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting
36 rabbits (72 eyes), four randomized groups
Source reviewed
PubMed-indexed abstract and bibliographic metadata checked via Europe PMC; full methods not appraised.
Study limitations
  • A negative result in one injury model does not settle other indications, but should accompany positive preclinical reports.
  • Animal outcomes do not establish human effectiveness or safety.

Reviewed 2026-10-07.

Read the source ↗

Observational study · 2025

Neuroprotective therapy in advanced primary open-angle glaucoma

The treated cohort had smaller annual declines in visual-field mean deviation and retinal nerve-fiber thickness than untreated controls. Intraocular pressure was controlled in both groups.

MD decline per year · 0.98 (0.78;1.76) versus 1.65 (0.59;1.79) dB/year

Study notes and original source
2025Uncontrolled human reportEnglish abstract

Neuroprotective therapy in advanced primary open-angle glaucoma

Retinalamin tissue-derived preparation

Dorofeev DA, Kozlova IV, Vereshchagina AI · Vestnik oftalmologii. 2025;141:75-80.

The treated cohort had smaller annual declines in visual-field mean deviation and retinal nerve-fiber thickness than untreated controls. Intraocular pressure was controlled in both groups.

Results and tables

Reported findings and study design

56 advanced-glaucoma patients, 98 eyes; prospective two-center observation, 2022–2024. Treated patients received ten IM injections of Retinalamin 5 mg every three months for two years.

Population or model 56 patients (98 eyes), advanced glaucoma; prospective two-center cohort, 2022–2024

Dose, route and schedule

Retinalamin: a course of ten intramuscular injections, 5 mg per injection, repeated every three months over two years. The abstract does not specify the interval between injections within each course.

Protocol source ↗ · Indexed publication abstract

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
MD decline per year0.98 (0.78;1.76) versus 1.65 (0.59;1.79) dB/year
PSD increase per year0.02 (−0.3;1.2) versus 0.3 (0.7;1.3) dB/year
RNFL loss per year1.5 (−0.25;5.0) versus 3.0 (0.75;10.2) μm/year

Parentheses reproduce the reported intervals without assuming their type. The control PSD interval does not contain its central value as printed; this inconsistency is retained.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting
56 patients (98 eyes), advanced glaucoma; prospective two-center cohort, 2022–2024
Source reviewed
PubMed-indexed abstract and bibliographic metadata checked via Europe PMC; full methods not appraised.
Study limitations
  • Nonrandomized cohort; treatment selection and other confounding may explain part of the difference.
  • The abstract does not establish a blinded comparison or a causal reduction in vision loss.

Reviewed 2026-10-07.

Read the source ↗

Randomized study in people · 2019

Structural and functional changes in the retina of patients with primary open-angle glaucoma and compensated intraocular pressure while undergoing retinoprotective therapy

Visual-field indices improved within the treated group while declining in controls. Visual acuity did not change; retinal nerve-fiber thickness and neuroretinal-rim volume remained stable in both groups. Electrophysiological results varied by measure.

Study notes and original source
2019Randomized trialEnglish abstract

Structural and functional changes in the retina of patients with primary open-angle glaucoma and compensated intraocular pressure while undergoing retinoprotective therapy

Retinalamin tissue-derived preparation

Egorov EA, Erichev VP, Strakhov VV, Petrov SY, Romanova TB, Vasina MV, Zinina VS, Makarova AS, Kazanova SY, Yartsev AV · Vestnik Oftalmologii. 2019;135(3):20–30.

Visual-field indices improved within the treated group while declining in controls. Visual acuity did not change; retinal nerve-fiber thickness and neuroretinal-rim volume remained stable in both groups. Electrophysiological results varied by measure.

Results and tables

Reported findings and study design

180 glaucoma patients, 355 eyes, randomized 90/90. IM Retinalamin course repeated at month 6; assessments at months 1, 3, 6, 7, 9 and 12.

Population or model 180 glaucoma patients (355 eyes), randomized equally; 12 months

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Visual-acuity changeNo change reportedTreated p=0.3732/0.6862; control p=0.7751
IOP changeNo significant changeTreated p=0.7632; control p=0.3921
MD, treated−5.52 ± 2.76 → −4.82 ± 2.73 dBSix visit p-values: 0.0391, 0.0201, 0.0302, 0.3708, 0.0151, 0.0353
MD, control−3.51 ± 1.84 → −4.60 ± 2.61 dBp=0.0012
PSD, treated4.63 ± 1.60 → 4.05 ± 1.43 dBp=0.0081
PSD, control3.73 ± 1.19 → 4.29 ± 1.53 dBp=0.0027
RNFL/neuroretinal rimDescribed as stableTreated p=0.8039/0.9005; control p=0.7448/0.9620
GCC thicknessTreated p=0.0377; control p=0.0250Source calls treated thickness stable despite p<0.05
Treated P50 amplitude6.54 ± 2.61 → 6.53 ± 2.64 μVp=0.0479
Treated P50 latency48.39 ± 3.69 → 50.86 ± 4.09 msp=0.0271
Control P50 amplitude/latencyAmplitude declined; latency increasedp=0.0031/0.0194
N95 amplitude/latencyTreated p=0.0141/0.0492; control p=0.0195/0.3401

Several “stable” descriptors conflict with printed p-values. Baseline group differences and multiple testing prevent treating each within-group p-value as a treatment effect.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting
180 glaucoma patients (355 eyes), randomized equally; 12 months
Source reviewed
PubMed-indexed abstract and bibliographic metadata checked via Europe PMC; full methods not appraised.
Study limitations
  • Baseline visual-field values differed. Within-group trends alone do not quantify a between-group treatment effect.
  • The analysis leaves blinding, adjustment for multiple comparisons and the handling of two eyes from the same patient unclear.

Reviewed 2026-10-07.

Read the source ↗

Review of earlier studies · 2013

Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results

Summarizes clinical work on seven named peptide preparations. Useful for tracing original Russian reports and distinguishing tissue extracts from short peptides.

Study notes and original source
2013ReviewEnglish abstract

Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results

Khavinson VKh, Kuznik BI, Ryzhak GA · Adv Gerontol 26(1):20-37. PMID 24003726

Summarizes clinical work on seven named peptide preparations. Useful for tracing original Russian reports and distinguishing tissue extracts from short peptides.

Population / setting
Originating group’s clinical and gerontology literature
Source reviewed
Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
  • Review by investigators in the originating program; not independent replication.
  • Clinical findings must be traced to the exact preparation and original study.

Reviewed 2026-09-29.

Read the source ↗

Comparison in people · 2020

Peptide bioregulators: delivery and efficacy

Compares administration routes of Retinalamin. Visual acuity did not change significantly; retinal-sensitivity results varied by disease stage and follow-up.

Group I total retinal-sensitivity change, initial/moderate/advanced disease · +122 / +166 / +124 dB · Month 3

Study notes and original source
2020Human comparative studyEnglish abstract

Peptide bioregulators: delivery and efficacy

Erichev VP, Lovpache DN, Yaremenko TV · Vestn Oftalmol 136(2):56-62. PMID 32366071

Compares administration routes of Retinalamin. Visual acuity did not change significantly; retinal-sensitivity results varied by disease stage and follow-up.

Results and tables

Reported findings and study design

498 glaucoma patients/eyes as printed; group I combined IM/retrobulbar 110, group II retrobulbar 171, group III IM (count not explicitly printed). Retinalamin 5 mg per stated route; total course 50 mg. Assessments months 3 and 6.

Population or model Open-angle glaucoma; 498 patients (eyes), as worded in the abstract

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Group I total retinal-sensitivity change, initial/moderate/advanced disease+122 / +166 / +124 dBMonth 3
Group II, initial/moderate disease+123 / +110 dBAdvanced disease: no significant change
Group III, initial/moderate/advanced disease+142 / +274 / +148 dB
DurabilityRegression described from month 6 in group III
Visual acuityNo significant change

These large dB totals sum threshold values across visual-field locations; they are not a single-point sensitivity increase. Patient/eye terminology is ambiguous in the abstract.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting
Open-angle glaucoma; 498 patients (eyes), as worded in the abstract
Source reviewed
Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
  • All compared groups received active preparation; this does not isolate benefit versus no Retinalamin.
  • Patient/eye unit wording should be checked in full text. Findings do not establish benefit for Normophthal.

Reviewed 2026-09-29.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗